Becker's ASC Review

10 ASC MANAGEMENT potential to be successful with us, and in the right markets. As we unlock markets, we will invigorate independent physicians and we'll have even more tools for growth and relevance on a national basis. Our multi- payer approach is strong, and we can mean- ingfully engage in the value discussion." In 2018, Optum reported a 17.4 percent year-over-year increase in revenue, hitting $101.3 billion. In the company's most recent fourth quarter and full year 2018 earnings call Optum CEO Andrew Witty mentioned he was thrilled with the progress of Optum- Helath and its ASCs. "I would expect roll out and to extend those networks over the next several years," he said. USPI In 2018, USPI invested $240 million in ambulatory mergers and acquisitions, add- ing 27 facilities and seven health system partners. e company anticipates deliver- ing another 10 percent to 12 percent growth in adjusted EBITDA less facility NCI in the coming year, focused on acquisitions and same-facility growth. Over the past year, USPI reported 5.1 percent same-facility revenue growth, and case volume increased 3.4 percent. "As we look at 2019, our pipeline continues to be robust," said USPI CEO Brett Brodnax during an earnings conference call in Febru- ary. "We have guided $150 million to $175 million [for acquisitions], but if we continue to find high quality acquisitions, it could be a little bit higher than that." USPI currently has ownership in around 5 percent of Medicare-certified ASCs nation- wide and the CEO of Dallas-based Tenet, USPI's parent company, Ron Rittenmeyer sees huge opportunity for future growth in the ASC space, although the company faces competition from other organizations in the market. "e primary competition that we continue to see is related to other surgery center companies that are playing in the space," said Mr. Brodnax, on the conference call. "We're also seeing a little bit of resurgence of competition from health systems around the country who are trying to figure out how they accelerate ambulatory growth. Now, With increasing regulatory pressure and the need to reduce costs while improving the patient experience, access to quality medicine is more important than ever. Leiters is an FDA-registered 503B outsourcing provider of high-quality solutions including: Patient-controlled analgesia (PCA) prefilled syringes ON-Q* Pain Relief System fill services Ophthalmology injections and solutions Learn how at leiters.com COMPOUNDING HEALTH™ Your journey to better medicine begins here. Intravenous (IV) injection prefilled syringes

• Cover